Articles tagged with “pharma-ai-investment”

AI Drug Discovery FDA Approvals: The 2026 Reality Check

Analyzes whether AI has discovered any FDA-approved drugs as of 2026, covering Insilico Medicine's rentosertib Phase III trial, Takeda's zasocitinib, clinical success rates, and billions in AI drug discovery investment.

40 min read

7/16/2026

ai drug discovery fda approvals ai drug discovery fda approvals insilico medicine rentosertib clinical trial success rate generative ai drug discovery pharma ai investment zasocitinib drug discovery timeline

Biotech AI Strategy: How to Prioritize Initiatives in 2026

A 2026 framework for biotech AI strategy: a five-axis prioritization matrix, FDA/EMA risk tiering, data readiness benchmarks, ROI data, and five named case studies including Insilico, Recursion, and Xaira.

45 min read

6/23/2026

biotech ai strategy ai in life sciences strategy ai prioritization framework pharma ai investment drug discovery ai roi ai roadmap biotech life sciences ai consulting fda ai guidance biotech ai use cases

Pharma AI Investment: Building a Board-Ready Business Case

Guide to structuring a board-ready business case for enterprise AI in pharma. Review investment planning, ROI metrics, implementation strategies, and use cases.

45 min read

4/15/2026

pharma ai investment enterprise ai adoption ai roi metrics pharmaceutical r&d healthcare ai strategy clinical trials ai ai business case